Literature DB >> 29850777

The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Harald Hampel1,2,3,4, M-Marsel Mesulam5, A Claudio Cuello6,7,8, Martin R Farlow9, Ezio Giacobini10, George T Grossberg11, Ara S Khachaturian12, Andrea Vergallo1,2,3,4, Enrica Cavedo1,2,3,4, Peter J Snyder13,14, Zaven S Khachaturian12.   

Abstract

Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29850777      PMCID: PMC6022632          DOI: 10.1093/brain/awy132

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  168 in total

Review 1.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

2.  Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Authors:  Lisa Mucha; Sara Shaohung; Brian Cuffel; Thomas McRae; Tami L Mark; Megan Del Valle
Journal:  J Manag Care Pharm       Date:  2008-06

3.  Autoradiographic evidence for flow-metabolism uncoupling during stimulation of the nucleus basalis of Meynert in the conscious rat.

Authors:  E Vaucher; J Borredon; G Bonvento; J Seylaz; P Lacombe
Journal:  J Cereb Blood Flow Metab       Date:  1997-06       Impact factor: 6.200

4.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

5.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

6.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

7.  Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease.

Authors:  H Schröder; E Giacobini; R G Struble; K Zilles; A Maelicke
Journal:  Neurobiol Aging       Date:  1991 May-Jun       Impact factor: 4.673

8.  The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.

Authors:  Wanda Lojkowska; Danuta Ryglewicz; Tomasz Jedrzejczak; Sławomira Minc; Teresa Jakubowska; Halina Jarosz; Anna Bochynska
Journal:  J Neurol Sci       Date:  2003-12-15       Impact factor: 3.181

9.  Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.

Authors:  Antoine Pariente; Catherine Helmer; Yvon Merliere; Nicholas Moore; Annie Fourrier-Réglat; Jean-Francois Dartigues
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-07       Impact factor: 2.890

10.  Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease.

Authors:  Mark Oremus; Christina Wolfson; Howard Bergman; Alain C Vandal
Journal:  Can J Aging       Date:  2007
View more
  239 in total

1.  Neuroprotective Effects of Apocynin and Galantamine During the Chronic Administration of Scopolamine in an Alzheimer's Disease Model.

Authors:  Eliezer Joseph; Daniel Miguel Ángel Villalobos-Acosta; Mónica Adriana Torres-Ramos; Eunice Dalet Farfán-García; Modesto Gómez-López; Ángel Miliar-García; Manuel Jonathan Fragoso-Vázquez; Iohanan Daniel García-Marín; José Correa-Basurto; Martha Cecilia Rosales-Hernández
Journal:  J Mol Neurosci       Date:  2019-11-25       Impact factor: 3.444

2.  Repetitive mild concussion in subjects with a vulnerable cholinergic system: Lasting cholinergic-attentional impairments in CHT+/- mice.

Authors:  Ajeesh Koshy Cherian; Natalie C Tronson; Vinay Parikh; Aaron Kucinski; Randy D Blakely; Martin Sarter
Journal:  Behav Neurosci       Date:  2019-03-21       Impact factor: 1.912

3.  Cholinergic nucleus 4 atrophy and gait impairment in Parkinson's disease.

Authors:  W Alex Dalrymple; Diane S Huss; Jamie Blair; Joseph L Flanigan; James Patrie; Scott A Sperling; Binit B Shah; Madaline B Harrison; T Jason Druzgal; Matthew J Barrett
Journal:  J Neurol       Date:  2020-07-28       Impact factor: 4.849

4.  Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats.

Authors:  Maricarmen Hernández-Rodríguez; Ivonne Maciel Arciniega-Martínez; Iohanan Daniel García-Marín; José Correa-Basurto; Martha Cecilia Rosales-Hernández
Journal:  Mol Neurobiol       Date:  2020-07-07       Impact factor: 5.590

5.  The effect of maslinic acid on cognitive dysfunction induced by cholinergic blockade in mice.

Authors:  Ho Jung Bae; Jihyun Kim; Jaehoon Kim; Nayeon Goo; Mudan Cai; Kyungnam Cho; Seo Yun Jung; Huiyoung Kwon; Dong Hyun Kim; Dae Sik Jang; Jong Hoon Ryu
Journal:  Br J Pharmacol       Date:  2020-04-01       Impact factor: 8.739

6.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

Review 7.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

8.  Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition?

Authors:  Donald E Moss
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

9.  The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates.

Authors:  Hui Liu; Zonghua Luo; Jiwei Gu; Yi Su; Hubert Flores; Stanley M Parsons; Yun Zhou; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharm Sci       Date:  2019-11-15       Impact factor: 4.384

10.  Advances in Drug Therapy for Alzheimer's Disease.

Authors:  Chuan-Cong Zhu; Si-Yu Fu; Yu-Xin Chen; Ling Li; Ruo-Lin Mao; Jian-Zhi Wang; Rong Liu; Yi Liu; Xiao-Chuan Wang
Journal:  Curr Med Sci       Date:  2021-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.